ESG Report 2025

Summary of the “Compliance Promotion Guidelines” Production of Promotional Materials: 1.Promotional materials must be produced through the relevant application process of the Corporate Culture and Publicity Department and may only be distributed after review and approval by the Marketing Department and the Legal Department. Under normal circumstances, regions or departments may not produce promotional materials on their own. 2.Promotional materials for public display and publicity at trade shows, exhibitions and similar events shall be submitted by the Company for an advertising approval number. 3.Unsubstantiated data or descriptions, or promotional statements beyond the approved scope, shall not be used. 4.Unauthorised third-party fonts and images shall not be used. 5.Assertions or guarantees of efficacy or safety shall not be included. 6.Content such as free gifts, prize-based sales, buy-one-get-one offers or tie-in sales of drugs shall not be included. Use of Promotional Materials: 1.All promotional materials must be displayed and used in accordance with the approved content, purpose and use, and must not be arbitrarily altered. 2.Prescription drug advertisements shall not be publicly displayed. 3.Materials for over-the-counter (OTC) drugs and health products bearing an advertising approval number may be displayed and used in permitted scenarios. 4.Promotional materials intended solely for internal training, academic conferences and similar purposes shall be promptly retrieved after the event. Training and Assessment: 1.All sales and promotion personnel must receive compliance training and comply with the compliance system. The Compliance Department is responsible for the training and for maintaining records. 2.The Compliance Department will conduct inspections of promotional activities, and compliance performance will be incorporated into performance appraisals. For those engaged in illegal conduct such as commercial bribery, the Company will restrict their eligibility for awards and promotions; in serious cases, employment contracts will be terminated, compensation liability will be pursued, the pharmaceutical representative's filing information will be deleted, and the reason will be publicly disclosed. Donation Practices: 1.Donation recipients are limited to public welfare social organisations or non-profit institutions with legal personality; donations shall not be made to any department or individual of any organisation. 2.Donations must be made in the Company's name through a donation agreement signed with the recipient organisation, which shall clearly specify the type, quantity, quality, value and purpose of the donated property, as well as the rights and obligations of both parties. 3.If the donated items are drugs, the national regulations on drug quality control shall be observed, ensuring that the drug quality meets the release standards and that the remaining shelf life is more than six months. 4.Public welfare donations shall not be linked to the Company's sales business. It is strictly prohibited to make donation conditional on the recommendation, purchase or use of the Company's products or any other form of benefit. 69 The United Laboratories International Holdings Limited 2025 Environmental, Social and Governance Report